Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
MINNEAPOLIS, & NICE, France, Jun 18, 2010 (BUSINESS WIRE) --Data from the FAST-PVI study, supported by Medtronic, Inc. (NYSE: MDT), shows lab time using anatomically-designed ablation catheters...
MINNEAPOLIS & NICE, France, Jun 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced European launch of the Protecta(TM)portfolio of implantable cardioverter-defibrillators (ICDs)...
MINNEAPOLIS, Jun 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo Securities 2010...
MINNEAPOLIS, Jun 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 31st Annual Healthcare...
MINNEAPOLIS, Jun 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the William Blair Growth Stock...
MINNEAPOLIS, Jun 07, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) announced today the launch of iPro(TM)2 Professional CGM, a continuous glucose monitoring (CGM) system used by physicians to...
MINNEAPOLIS, Jun 02, 2010 (BUSINESS WIRE) --In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson's disease, Medtronic DBS Therapy was shown to improve motor...
MINNEAPOLIS, May 03, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), today announced completion of patient enrollment in the first of two studies in the company's CURE-AF (Concomitant...
PARIS, May 26, 2010 (BUSINESS WIRE) --New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve...
MINNEAPOLIS, May 25, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT): First $4 Billion Sales Quarter in Company History Full Year Revenue of $15.8 Billion Increased 8 Percent Full Year Non-GAAP...